<!DOCTYPE html SYSTEM "about:legacy-compat">
<html lang="en-US" class="no-js">
  <head>
    <meta charset="utf-8"/>
    <title>D.C. Law 23-133. Access to Biosimilars Amendment Act of 2020. | D.C. Law Library</title>
    <link rel="shortcut icon" href="/us/dc/_document/v2/images/favicons/favicon.ico"/>
    <!--Meta-->
    <meta http-equiv="X-UA-Compatible" content="IE=EDGE"/>
    <meta name="viewport" content="width=device-width, initial-scale=1"/>
    <meta name="format-detection" content="telephone=no"/>
    <meta name="HandheldFriendly" content="true"/>
    <meta itemprop="full-html" content="/us/dc/council/laws/23-133/index.full.html"/>
    <meta itemprop="toc-json" content="/us/dc/council/laws/23-133/index.json"/>
    <meta itemprop="doc-type" content="document"/>
    <meta itemprop="ref-doc" content="D.C. Law 23-133"/>
    <!--OpenGraph-->
    <meta property="og:url" content="https://code.dccouncil.us/us/dc/council/laws/23-133"/>
    <meta property="og:type" content="article"/>
    <meta property="og:title" content="D.C. Law 23-133. Access to Biosimilars Amendment Act of 2020. | D.C. Law Library"/>
    <meta property="og:image" content="https://code.dccouncil.us/us/dc/_document/v2/images/og/og_image.png"/>
    <!--Progressive Web App-->
    <link rel="manifest" href="/manifest.json"/>
    <meta name="msapplication-config" content="/browserconfig.xml"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="apple-mobile-web-app-status-bar-style" content="#000000"/>
    <meta name="apple-mobile-web-app-title" content="D.C. Law Library"/>
    <meta name="theme-color" content="#000000"/>
    <meta name="msapplication-navbutton-color" content="#000000"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="mobile-web-app-capable" content="yes"/>
    <!--PWA icons-->
    <link rel="apple-touch-icon" sizes="180x180" href="/us/dc/_document/v2/images/favicons/apple-touch-icon.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="60x60" href="/us/dc/_document/v2/images/favicons/apple-touch-icon-60x60-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="76x76" href="/us/dc/_document/v2/images/favicons/apple-touch-icon-76x76-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="/us/dc/_document/v2/images/favicons/apple-touch-icon-152x152-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="180x180" href="/us/dc/_document/v2/images/favicons/apple-touch-icon-180x180-precomposed.png"/>
    <link rel="mask-icon" href="/us/dc/_document/v2/images/favicons/safari-pinned-tab.svg" color="#000000"/>
    <link rel="icon" type="image/png" sizes="16x16" href="/us/dc/_document/v2/images/favicons/favicon-16x16.png"/>
    <link rel="icon" type="image/png" sizes="32x32" href="/us/dc/_document/v2/images/favicons/favicon-32x32.png"/>
    <link rel="icon" type="image/png" sizes="48x48" href="/us/dc/_document/v2/images/favicons/favicon-48x48.png"/>
    <!--Fonts-->
    <link href="/us/dc/_document/v2/biticons/biticons.css" type="text/css" rel="stylesheet"/>
    <link href="/us/dc/_document/v2/fonts/droid-serif/droid-serif.css" type="text/css" rel="stylesheet"/>
    <link href="/us/dc/_document/v2/fonts/open-sans/open-sans.css" type="text/css" rel="stylesheet"/>
    <!--Document CSS-->
    <link href="/us/dc/_document/v2/styles/responsive.min.css" type="text/css" rel="stylesheet" media="screen"/>
    <link href="/us/dc/_document/v2/styles/main.min.css" type="text/css" rel="stylesheet" media="screen"/>
    <link href="/us/dc/_document/v2/styles/print.min.css" type="text/css" rel="stylesheet" media="print"/>
    <link href="/_reader/styles/main.min.css" type="text/css" rel="stylesheet"/>
    <script src="/_reader/js/main.js"> </script>
    <!--Links to resources that need to be prefetched-->
    <link rel="prefetch" href="/us/dc/council/laws/23-133/index.full.html" as="fetch"/>
  </head>
  <body>
    <div role="region" id="announcer" aria-live="polite" class="sr-only" aria-atomic="true" aria-label="Live messages">
      <p id="message"> </p>
    </div>
    <nav class="visually-hidden">
      <a href="#area__content" class="skip-link">Skip to main content</a>
    </nav>
    <div id="grid" class="ns__document__us-dc">
      <header id="section__header" class="ns__document__us-dc">
        <div id="section__header__inner" class="ns__document__us-dc">
          <div id="area__logo" class="ns__document__us-dc">
            <a href="/" class="logo" aria-label="Logo - Return to home page">
              <img src="/us/dc/_document/v2/images/logo/dc-seal-outline.png" srcset="/us/dc/_document/v2/images/logo/dc-seal-outline.png 1x, /us/dc/_document/v2/images/logo/dc-seal-outline@2x.png 2x" alt="Council of the District of Columbia logo"/>
            </a>
          </div>
          <div id="area__main_title" class="ns__document__us-dc">
            <img src="/us/dc/_document/v2/images/logo/dccouncil_typemark.svg" srcset="" alt="D.C. Law Library"/>
          </div>
        </div>
      </header>
      <div id="section__content" class="ns__document__us-dc">
        <div id="section__content__inner" class="ns__document__us-dc">
          <section id="area__breadcrumbs" class="ns__document__us-dc" role="region" aria-label="Breadcrumbs">
            <input type="checkbox" id="menu-trigger" class="menu-trigger" aria-label="Mobile menu toggler"/>
            <label for="menu-trigger">
              <span class="visually-hidden">Toggle mobile menu</span>
            </label>
            <nav role="navigation" aria-label="Breadcrumb navigation">
              <div class="h__ui">Navigation</div>
              <ul class="ancestors">
                <li data-search-path="library|D.C. Code" aria-hidden="true" data-search-heading="D.C. Code" data-search-default="true" class="hidden"/>
                <li data-search-path="library" data-search-heading="All Documents" class="no-indent">
                  <a href="/" title="D.C. Law Library">D.C. Law Library</a>
                </li>
                <li data-search-path="library|dclaws" data-search-heading="D.C. Laws" class="no-indent">
                  <a href="/dclaws" title="D.C. Laws Codified in the D.C. Code">D.C. Laws Codified in the D.C. Code</a>
                </li>
                <li data-search-path="library|dclaws|23" data-search-heading="" class="no-indent">
                  <a href="/dclaws/23" title="Council Period 23 (2019-2020)">Council Period 23 (2019-2020)</a>
                </li>
                <li data-search-path="library|dclaws|23|permanent" data-search-heading="" class="no-indent">
                  <a href="/dclaws/23/permanent" title="Permanent Laws">Permanent Laws</a>
                </li>
                <li data-search-path="library|dclaws|23|permanent|D.C. Law 23-133" data-search-heading="" class="li__book-open">
                  <span title="D.C. Law 23-133. Access to Biosimilars Amendment Act of 2020.">D.C. Law 23-133. Access to Biosimilars Amendment Act of 2020.</span>
                </li>
              </ul>
            </nav>
          </section>
          <main id="area__content" class="ns__document__us-dc">
            <article class="content" role="document">
              <div class="tuf-authenticate">
                <h1 class="h__toc" id="/us/dc/council/laws/23-133">D.C. Law 23-133. Access to Biosimilars Amendment Act of 2020.</h1>
                <p class="text--center">AN ACT</p>
                <p class="text--italic">To amend the District of Columbia Prescription Drug Price Information Act to authorize licensed pharmacists to dispense interchangeable biological products, and to require notifications to physicians, with certain exceptions, when interchangeable biological products are dispensed.</p>
                <p>BE IT ENACTED BY THE COUNCIL OF THE DISTRICT OF COLUMBIA, That this act may be cited as the "Access to Biosimilars Amendment Act of 2020".</p>
                <p id="&#xA7;2"><span class="level-num">Sec. 2. </span>The District of Columbia Prescription Drug Price Information Act, effective September 10, 1976 (D.C. Law 1-81; D.C. Official Code § 48-801.01 <em>et seq.</em>), is amended as follows:</p>
                <aside class="marginalia" role="note">
                  <p>
                    <span class="text--bold">Amend <a class="no-wrap" href="/us/dc/council/code/sections/48-804.51">§ 48-804.51</a></span>
                  </p>
                </aside>
                <p class="text-indent-1"><span class="level-num" id="/us/dc/council/laws/23-133#&#xA7;2(a)">(a)</span> Section 2 (D.C. Official Code § 48-804.51) is amended by adding new paragraphs (1A) and (2A) to read as follows:</p>
                <p class="text-indent-2 quote">"<span class="level-num">(1A)</span> "Biological product" shall have the same meaning as provided in 42 U.S.C. § 262.</p>
                <p class="text-indent-2 quote">"<span class="level-num">(2A)</span> "Interchangeable biological product" means a biological product that is:</p>
                <p class="text-indent-3 quote">"<span class="level-num">(A)</span> Licensed and determined by the United States Food and Drug Administration to meet the standards for interchangeability under 42 U.S.C. § 262(k)(4); or</p>
                <p class="text-indent-3 quote">"<span class="level-num">(B)</span> Determined to be biosimilar to and interchangeable with a reference biological product as stated in the latest edition of, or supplement to, the United States and Food and Drug administration's ("FDA") publication, "Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations" (known as the Purple Book).".</p>
                <aside class="marginalia" role="note">
                  <p>
                    <span class="text--bold">Amend <a class="no-wrap" href="/us/dc/council/code/sections/48-803.01">§ 48-803.01</a></span>
                  </p>
                </aside>
                <p class="text-indent-1"><span class="level-num" id="/us/dc/council/laws/23-133#&#xA7;2(b)">(b)</span> Section 301 (D.C. Official Code § 48-803.01) is amended by adding a new subsection (d) to read as follows:</p>
                <p class="text-indent-1 quote">"<span class="level-num">(d)</span> The Board of Pharmacy and the Board of Medicine shall maintain a link on their websites to the current list of biological products determined by the FDA to be interchangeable with a specific biological product.".</p>
                <aside class="marginalia" role="note">
                  <p>
                    <span class="text--bold">Amend <a class="no-wrap" href="/us/dc/council/code/sections/48-803.02">§ 48-803.02</a></span>
                  </p>
                </aside>
                <p class="text-indent-1"><span class="level-num" id="/us/dc/council/laws/23-133#&#xA7;2(c)">(c)</span> Section 302 (D.C. Official Code § 48-803.02) is amended as follows:</p>
                <p class="text-indent-2"><span class="level-num" id="/us/dc/council/laws/23-133#&#xA7;2(c)(1)">(1)</span> The section heading is amended to read as follows:</p>
                <p id="" class="quote">"<span class="level-num">Sec. 302. </span>Dispensing of generically equivalent drug product or interchangeable biological product.</p>
                <p class="text-indent-2"><span class="level-num" id="/us/dc/council/laws/23-133#&#xA7;2(c)(2)">(2)</span> Subsection (a) is amended by striking the phrase "generically equivalent drug product" wherever it appears and inserting the phrase "generically equivalent drug product or interchangeable biological product" in its place.</p>
                <p class="text-indent-2"><span class="level-num" id="/us/dc/council/laws/23-133#&#xA7;2(c)(3)">(3)</span> Subsection (b) is amended by striking the phrase "drug by generic name" and inserting the phrase "drug by generic name or interchangeable biological product" in its place.</p>
                <aside class="marginalia" role="note">
                  <p>
                    <span class="text--bold">Amend <a class="no-wrap" href="/us/dc/council/code/sections/48-803.03">§ 48-803.03</a></span>
                  </p>
                </aside>
                <p class="text-indent-1"><span class="level-num" id="/us/dc/council/laws/23-133#&#xA7;2(d)">(d)</span> Section 303(2) (D.C. Official Code § 48-803.03(2)) is amended by striking the phrase "generically equivalent drug product" and inserting the phrase "generically equivalent drug product or interchangeable biological product" in its place.</p>
                <aside class="marginalia" role="note">
                  <p>
                    <span class="text--bold">Amend <a class="no-wrap" href="/us/dc/council/code/sections/48-803.03a">§ 48-803.03a</a></span>
                  </p>
                </aside>
                <p class="text-indent-1"><span class="level-num" id="/us/dc/council/laws/23-133#&#xA7;2(e)">(e)</span> Section 303a(a) (D.C. Official Code § 48-803.03a(a)) is amended by striking the phrase "drug substitution" and inserting the phrase "drug substitution, including an interchangeable biological product," in its place.</p>
                <aside class="marginalia" role="note">
                  <p>
                    <span class="text--bold">Amend <a class="no-wrap" href="/us/dc/council/code/sections/48-803.04">§ 48-803.04</a></span>
                  </p>
                </aside>
                <p class="text-indent-1"><span class="level-num" id="/us/dc/council/laws/23-133#&#xA7;2(f)">(f)</span> Section 304 (D.C. Official Code § 48-803.04) is amended by striking the phrase "substituted under this title," and inserting the phrase "substituted under this title, including the substitution of an interchangeable biological product," in its place.</p>
                <aside class="marginalia" role="note">
                  <p>
                    <span class="text--bold">Amend <a class="no-wrap" href="/us/dc/council/code/sections/48-803.05">§ 48-803.05</a></span>
                  </p>
                </aside>
                <p class="text-indent-1"><span class="level-num" id="/us/dc/council/laws/23-133#&#xA7;2(g)">(g)</span> Section 305 (D.C. Official Code § 48-803.05) is amended as follows:</p>
                <p class="text-indent-2"><span class="level-num" id="/us/dc/council/laws/23-133#&#xA7;2(g)(1)">(1)</span> Subsection (a) is amended by striking the phrase "under this title" and inserting the phrase "under this title, including the substitution of an interchangeable biological product" in its place.</p>
                <p class="text-indent-2"><span class="level-num" id="/us/dc/council/laws/23-133#&#xA7;2(g)(2)">(2)</span> Subsection (b) is amended by striking the phrase "generically equivalent drug products drugs" and inserting the phrase "generically equivalent drugs products or an interchangeable biological product" in its place.</p>
                <aside class="marginalia" role="note">
                  <p>
                    <span class="text--bold">New <a class="no-wrap" href="/us/dc/council/code/sections/48-803.06">§ 48-803.06</a></span>
                  </p>
                </aside>
                <p class="text-indent-1"><span class="level-num" id="/us/dc/council/laws/23-133#&#xA7;2(h)">(h)</span> A new section 306 is added to read as follows:</p>
                <p id="" class="quote">"<span class="level-num">Sec. 306. </span>Pharmacist notification to prescriber of substitution of interchangeable biological product.</p>
                <p class="text-indent-1 quote">"<span class="level-num">(a)</span> Within 5 business days after dispensing a biological product to a patient, the dispensing pharmacist or the pharmacist's designee shall communicate to the prescriber the specific biological product dispensed, including the name and manufacturer of the biological product; except, that this communication shall not be required if the FDA has not approved an interchangeable biological product for the biological product prescribed to the patient or a refill prescription is not changed from the biological product dispensed on the most recent filling of the prescription.</p>
                <p class="text-indent-1 quote">"<span class="level-num">(b)</span><span class="level-num">(1)</span> Except as provided under subsection (c) of this section, the communication required under subsection (a) of this section shall be provided by making an entry that is electronically accessible to the health care provider through:</p>
                <p class="text-indent-3 quote">"<span class="level-num">(A)</span> An interoperable electronic medical records system;</p>
                <p class="text-indent-3 quote">"<span class="level-num">(B)</span> An electronic prescribing technology; or</p>
                <p class="text-indent-3 quote">"<span class="level-num">(C)</span> A pharmacy benefits management system.</p>
                <p class="text-indent-2 quote">"<span class="level-num">(2)</span> Making an entry through a mechanism listed in paragraph (1) of this subsection shall be presumed to provide the communication to the prescriber required under subsection (a) of this section.</p>
                <p class="text-indent-1 quote">"<span class="level-num">(c)</span> If the mechanisms listed in subsection (b)(1) of this section are unavailable, the communication required under subsection (a) of this section may be provided by facsimile, telephone, electronic transmission, or other means.</p>
                <p class="text-indent-1 quote">"<span class="level-num">(d)</span> The requirements under subsections (a) through (c) of this section shall not apply to dispensing pharmacists or their designees at a health maintenance organization that operates as a group model for services furnished through internal pharmacy operations for members and patients of the health maintenance organization.".</p>
                <p id="&#xA7;3"><span class="level-num">Sec. 3. </span>Fiscal impact statement.</p>
                <p>The Council adopts the fiscal impact statement in the committee report as the fiscal impact statement required by section 4a of the General Legislative Procedures Act of 1975, approved October 16, 2006 (120 Stat. 2038; D.C. Official Code § 1-301.47a).</p>
                <p id="&#xA7;4"><span class="level-num">Sec. 4. </span>Effective date.</p>
                <p>This act shall take effect following approval by the Mayor (or in the event of veto by the</p>
                <p>Mayor, action by the Council to override the veto), a 30-day period of congressional review as provided in section 602(c)(l) of the District of Columbia Home Rule Act, approved December 24, 1973 (87 Stat. 813; D.C. Official Code § 1-206.02(c)(l)), and publication in the District of Columbia Register.</p>
              </div>
            </article>
          </main>
          <section id="area__document_meta" class="ui ns__document__us-dc">
            <h2 class="h__ui">Law Information</h2>
            <section>
              <h3 class="h__ui--small">Cites</h3>
              <ul>
                <li>D.C. Law 23-133 (<a class="internal-link" href="https://lims.dccouncil.us/downloads/LIMS/43164/Signed_Act/B23-0430-Signed_Act.pdf">PDF</a>)</li>
                <li>D.C. Act 23-387 (<a class="internal-link" href="https://lims.dccouncil.us/downloads/LIMS/43164/Signed_Act/B23-0430-Signed_Act.pdf">PDF</a>)</li>
                <li>67 DCR 9880</li>
              </ul>
            </section>
            <section>
              <h3 class="h__ui--small">Effective</h3>
              <p>Oct. 20, 2020</p>
              <h3 class="h__ui--small">Legislative History (<a href="https://lims.dccouncil.us/Legislation/B23-0430">LIMS</a>)</h3>
              <p>Law 23-133, the “Access to Biosimilars Amendment Act of 2020,” was introduced in the Council and assigned Bill No. 23-430 which was referred to the Health. The bill was adopted on first and second readings on July 7, 2020, and July 21, 2020, respectively. After mayoral review, it was assigned Act No. 23-387 on Aug. 13, 2020, and transmitted to Congress for its review. D.C. Law 23-133 became effective Oct. 20, 2020.</p>
            </section>
          </section>
        </div>
      </div>
      <footer id="section__footer" class="ns__document__us-dc">
        <div id="section__footer__inner" class="ns__document__us-dc">
          <section id="area__footer__logo" class="ns__document__us-dc">
            <a href="/" class="logo" aria-label="Logo - Return to home page">
              <img src="/us/dc/_document/v2/images/logo/dc-seal.png" srcset="/us/dc/_document/v2/images/logo/dc-seal.png 1x, /us/dc/_document/v2/images/logo/dc-seal@2x.png 2x" alt="Council of the District of Columbia logo"/>
            </a>
          </section>
          <div id="area__footer__content" class="ns__document__us-dc">
            <p>The codes and laws on this website are in the public domain.</p>
            <p>
      Please do not scrape. Instead, bulk download the <a href="https://github.com/dccouncil/law-html">HTML</a> or <a href="https://github.com/dccouncil/law-xml">XML</a>.
    </p>
            <p>Powered by the non-profit <a href="http://www.openlawlib.org/">Open Law Library</a>.</p>
          </div>
        </div>
      </footer>
    </div>
    <!--Piwik analytics-->
    <noscript>
      <img src="/_analytics/pixel.png" style="border:0;" alt=""/>
    </noscript>
  </body>
</html>
